---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107743"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:38:32.181429+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports Q1 FY2026 net loss $18.2M; Phase 3 sunRIZE topline due Dec 2025

## Summary
- Cash & marketable securities $152.2M as of Sep 30, 2025, down from $167.9M on Jun 30.
- Net loss $18.2M for Q1 FY2026 vs $15.4M a year ago; R&D $13.1M, G&A $6.7M.
- Phase 3 sunRIZE (congenital HI) topline results expected December 2025; registrational alignment with FDA.
- Streamlined single-arm Phase 3 upLIFT (tumor HI) enrollment underway; topline data H2 2026.
- Virtual investor event Nov 10, 2025 featuring KOLs on commercial opportunity for ersodetug.

## SEC filing metadata
- accession: 0001104659-25-107743
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/0001104659-25-107743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/tm2529989d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107743
- JSON: https://secwatch.observer/filing/0001104659-25-107743.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.